Skip to main content
ARQT logo

Arcutis Biotherapeutics, Inc.

ARQTNASDAQHealthcareBiotechnology

$28.84Today:- (-)1Y +39.37%

As of Oct 16, 2026 close

Market cap
$3.95B
P/E (TTM)
138.67
Forward P/E
-
Dividend yield
-
52-week range
$19.30$31.77
Volume (live)
-
Avg. volume (3M)
3.09M

Arcutis Biotherapeutics (ARQT) Income Statement

Arcutis Biotherapeutics reported revenue of $376.07M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 91.3% from $196.54M a year earlier. Arcutis Biotherapeutics posted a net loss of $16.14M, compared with a net loss of $140.04M a year earlier. Gross margin was 90.2% and operating margin -3.3%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $129.86M, up 59.3% from the same quarter a year earlier.

Arcutis Biotherapeutics Income Statement Analysis

Values in millions USD

Scroll to see more
Arcutis Biotherapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue376.07196.5459.613.690.000.000.000.000.00
Cost of Revenue36.7019.134.990.750.760.460.200.000.00
Gross Profit339.38177.4154.622.93-0.76-0.46-0.200.000.00
Operating Expenses
Research & Development77.0576.42110.58182.44145.56115.3136.5217.943.41
Selling, General & Administrative274.55229.39185.15122.1260.9720.886.421.800.70
Operating Expenses351.60305.81295.72304.56205.77136.1942.9419.744.11
Operating Income-12.23-128.40-241.10-301.63-206.53-136.65-43.13-19.74-4.11
Other Income/Expense
Interest Income8.9016.1312.525.820.170.971.140.000.00
Interest Expense12.0827.17-29.71-15.650.000.000.000.000.00
Other Income/Expense0.440.05-17.93-9.830.170.971.140.48-0.87
Income
Income Before Tax-14.97-139.39-259.03-311.46-206.36-135.68-42.00-19.26-4.98
Income Tax Expense1.170.653.110.000.000.000.000.000.00
Net Income-16.14-140.04-262.14-311.46-206.36-135.68-42.00-19.26-4.98
Net Income - Continuous Operations-16.14-140.04-262.14-311.46-206.36-135.68-42.00-19.26-4.98
Net Income - Discontinued Operations---------
EBITDA1.78-110.27-240.35-300.69-205.59-135.22-41.800.48-0.87
EBIT-2.89-112.22-241.10-301.63-206.36-136.65---
Depreciation & Amortization4.671.961.520.930.760.460.2019.744.11
Earnings Per Share
Basic EPS--1.00-4.00-6.00-4.00-4.00-1.00-1.00-5.00
Diluted EPS--1.00-4.00-6.00-4.00-4.00-1.00-1.00-5.00
Basic Shares Outstanding127.23120.9669.3155.0349.4135.6738.0936.241.06
Diluted Shares Outstanding127.23120.9669.3155.0349.4135.6738.0936.241.06

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Arcutis Biotherapeutics Financial Statements

What was Arcutis Biotherapeutics's revenue in fiscal 2025?

Arcutis Biotherapeutics reported revenue of $376.07M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 91.3% from $196.54M a year earlier.

Is Arcutis Biotherapeutics profitable?

No. Arcutis Biotherapeutics reported a net loss of $16.14M in fiscal 2025. In fiscal 2024 it lost $140.04M.

What is Arcutis Biotherapeutics's operating margin?

Arcutis Biotherapeutics's operating income was −$12.23M on revenue of $376.07M in fiscal 2025, an operating margin of -3.3%, compared with -65.3% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition